{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T22:31:38Z","timestamp":1769812298396,"version":"3.49.0"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":915,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1111\/bjd.12045","type":"journal-article","created":{"date-parts":[[2012,9,17]],"date-time":"2012-09-17T16:26:21Z","timestamp":1347899181000},"page":"609-616","source":"Crossref","is-referenced-by-count":84,"title":["Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting"],"prefix":"10.1093","volume":"168","author":[{"given":"R.","family":"Navarro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Vilarrasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Herranz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Puig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Bordas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"Carrascosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Taberner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ferr\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Garc\u00eda-Bustinduy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Romero-Mat\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Pedragosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Garc\u00eda-Diez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Daud\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2013,2,28]]},"reference":[{"key":"10.1111\/bjd.12045-BIB1|cit1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-3083.2009.03389.x","article-title":"European S3-guidelines on the systemic treatment of psoriasis vulgaris","volume":"23","author":"Pathirana","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/bjd.12045-BIB2|cit2","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"key":"10.1111\/bjd.12045-BIB3|cit3","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jaad.2004.02.021","article-title":"Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial","volume":"51","author":"Gottlieb","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.12045-BIB4|cit4","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1365-2133.2010.09791.x","article-title":"A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol\/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study","volume":"163","author":"Tha\u00e7i","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.12045-BIB5|cit5","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jaad.2006.05.027","article-title":"Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study","volume":"55","author":"Gordon","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.12045-BIB6|cit6","first-page":"928","article-title":"Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study","volume":"9","author":"Leonardi","year":"2010","journal-title":"J Drugs Dermatol"},{"key":"10.1111\/bjd.12045-BIB7|cit7","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1365-2133.2005.06306.x","article-title":"Safety and efficacy study on etanercept in patients with plaque psoriasis","volume":"152","author":"Costanzo","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.12045-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"10.1111\/bjd.12045-BIB9|cit9","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"10.1111\/bjd.12045-BIB10|cit10","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0001-7310(10)70012-0","article-title":"Etanercept and infections","volume":"101","author":"Ribera","year":"2010","journal-title":"Actas Dermosifiliogr"},{"key":"10.1111\/bjd.12045-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1136\/ard.62.11.1078","article-title":"Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection","volume":"62","author":"Peterson","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/bjd.12045-BIB12|cit12","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/art.20702","article-title":"Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection","volume":"51","author":"Parke","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1111\/bjd.12045-BIB13|cit13","first-page":"107","article-title":"Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C","volume":"31","author":"Oniankitan","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1111\/bjd.12045-BIB14|cit14","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/gut.2004.040675","article-title":"Chronic hepatitis B reactivation following infliximab therapy in Crohn\u2019s disease patients: need for primary prophylaxis","volume":"53","author":"Esteve","year":"2004","journal-title":"Gut"},{"key":"10.1111\/bjd.12045-BIB15|cit15","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1136\/ard.62.7.686","article-title":"Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate","volume":"62","author":"Ostuni","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/bjd.12045-BIB16|cit16","first-page":"1624","article-title":"Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still\u2019s disease","volume":"30","author":"Michel","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1111\/bjd.12045-BIB17|cit17","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1002\/art.21216","article-title":"Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab","volume":"52","author":"Anelli","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1111\/bjd.12045-BIB18|cit18","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1093\/rheumatology\/kel123","article-title":"Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis","volume":"45","author":"Roux","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1111\/bjd.12045-BIB19|cit19","first-page":"421","article-title":"Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis","volume":"35","author":"Cansu","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1111\/bjd.12045-BIB20|cit20","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10067-006-0394-z","article-title":"Inhibition of TNFalpha does not induce viral reactivation in patients with chronic hepatitis C infection: two cases","volume":"26","author":"Aslanidis","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1111\/bjd.12045-BIB21|cit21","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/rheumatology\/kel191","article-title":"Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus","volume":"46","author":"Marotte","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1111\/bjd.12045-BIB22|cit22","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3748\/wjg.v12.i6.974","article-title":"Subfulminant hepatitis B after infliximab in Crohn\u2019s disease: need for HBV-screening?","volume":"12","author":"Millonig","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1111\/bjd.12045-BIB23|cit23","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/j.1365-2133.2008.08851.x","article-title":"The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature","volume":"159","author":"Domm","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.12045-BIB24|cit24","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/rheumatology\/ker190","article-title":"Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review","volume":"50","author":"Brunasso","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1111\/bjd.12045-BIB25|cit25","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.jaad.2004.05.013","article-title":"Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases","volume":"51","author":"Magliocco","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.12045-BIB26|cit26","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.jaad.2008.09.057","article-title":"Infliximab treatment for severe psoriasis in a patient with active hepatitis B virus infection","volume":"60","author":"Conde-Taboada","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.12045-BIB27|cit27","first-page":"808","article-title":"Efficacy and safety of etanercept in patients with psoriasis and hepatitis C","volume":"20","author":"Ventura","year":"2010","journal-title":"Eur J Dermatol"},{"key":"10.1111\/bjd.12045-BIB28|cit28","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1177\/039463201002300335","article-title":"Etanercept therapy in patients with psoriasis and concomitant HCV infection","volume":"23","author":"Garavaglia","year":"2010","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1111\/bjd.12045-BIB29|cit29","first-page":"645","article-title":"Tumour necrosis factor-\u03b1 antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients","volume":"164","author":"Prignano","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.12045-BIB30|cit30","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1468-3083.2010.03754.x","article-title":"Safety of anti-tumour necrosis factor-\u03b1 agents in psoriasis patients who were chronic hepatitis B carriers: a retrospective report of seven patients and brief review of the literature","volume":"25","author":"Fotiadou","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/bjd.12045-BIB31|cit31","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/MD.0b013e3182380a76","article-title":"Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy","volume":"90","author":"P\u00e9rez-Alvarez","year":"2011","journal-title":"Medicine (Baltimore)"},{"key":"10.1111\/bjd.12045-BIB32|cit32","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0168-8278(99)80060-9","article-title":"Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity","volume":"30","author":"Zylberberg","year":"1999","journal-title":"J Hepatol"},{"key":"10.1111\/bjd.12045-BIB33|cit33","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1046\/j.1365-2249.1997.4861382.x","article-title":"Serum levels of IL-10, IL-15 and soluble tumour necrosis factor-alpha (TNF-alpha) receptors in type C chronic liver disease","volume":"109","author":"Kakumu","year":"1997","journal-title":"Clin Exp Immunol"},{"key":"10.1111\/bjd.12045-BIB34|cit34","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2004.11.025","article-title":"Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study","volume":"42","author":"Zein","year":"2005","journal-title":"J Hepatol"},{"key":"10.1111\/bjd.12045-BIB35|cit35","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.0022-202X.2004.23488.x","article-title":"The IL-12 family member p40 chain as a master switch and novel therapeutic target in psoriasis","volume":"123","author":"Nestle","year":"2004","journal-title":"J Invest Dermatol"},{"key":"10.1111\/bjd.12045-BIB36|cit36","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1086\/517446","article-title":"Induction of interleukin-12 production in chronic hepatitis C virus infection correlates with the hepatocellular damage","volume":"178","author":"Quiroga","year":"1998","journal-title":"J Infect Dis"},{"key":"10.1111\/bjd.12045-BIB37|cit37","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1440-1746.2003.03329.x","article-title":"Ribavirin upregulates interleukin-12 receptor and induces T cell differentiation towards type 1 in chronic hepatitis C","volume":"19","author":"Shiina","year":"2004","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1111\/bjd.12045-BIB38|cit38","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0166-3542(01)00183-8","article-title":"Interleukin-12 in the treatment of chronic hepatitis B and C","volume":"52","author":"Zeuzem","year":"2001","journal-title":"Antiviral Res"},{"key":"10.1111\/bjd.12045-BIB39|cit39","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S0001-7310(10)70015-6","article-title":"Etanercept and neoplasms","volume":"101","author":"Garc\u00eda-Rabasco","year":"2010","journal-title":"Actas Dermosifiliogr"},{"key":"10.1111\/bjd.12045-BIB40|cit40","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/carcin\/bgr054","article-title":"The prevention of infection-associated cancers","volume":"32","author":"De Flora","year":"2011","journal-title":"Carcinogenesis"},{"key":"10.1111\/bjd.12045-BIB41|cit41","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.semarthrit.2007.10.011","article-title":"Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection","volume":"38","author":"Carroll","year":"2008","journal-title":"Semin Arthritis Rheum"},{"key":"10.1111\/bjd.12045-BIB42|cit42","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMra031087","article-title":"Hepatitis B virus infection - natural history and clinical consequences","volume":"350","author":"Ganem","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1111\/bjd.12045-BIB43|cit43","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1365-2893.1997.tb00185.x","article-title":"Studies of interleukin-12 in chronic hepatitis B virus infection","volume":"4","author":"Naoumov","year":"1997","journal-title":"J Viral Hepat"},{"key":"10.1111\/bjd.12045-BIB44|cit44","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1172\/JCI119498","article-title":"Interleukin-12 induction of Th1 cytokines is important for viral clearance in chronic hepatitis B","volume":"99","author":"Rossol","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1111\/bjd.12045-BIB45|cit45","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/hep.20888","article-title":"Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity","volume":"42","author":"Rigopoulou","year":"2005","journal-title":"Hepatology"},{"key":"10.1111\/bjd.12045-BIB46|cit46","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-2133.2005.06893.x","article-title":"British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005","volume":"153","author":"Smith","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.12045-BIB47|cit47","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1157\/13087150","article-title":"Reactivation of hepatitis B treated with adefovir after infliximab administration","volume":"126","author":"N\u00fa\u00f1ez-Rodr\u00edguez","year":"2006","journal-title":"Med Clin (Barc)"},{"key":"10.1111\/bjd.12045-BIB48|cit48","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0001-7310(10)70014-4","article-title":"Etanercept and chronic infection by HCV and HBV","volume":"101","author":"Bordas","year":"2010","journal-title":"Actas Dermosifiliogr"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.12045","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/bjd.12045\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T14:02:54Z","timestamp":1676383374000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/168\/3\/609\/6614530"}},"subtitle":["Safety and efficacy of biologics in patients with psoriasis and chronic viral hepatitis"],"short-title":[],"issued":{"date-parts":[[2013,2,28]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.12045","relation":{},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2,28]]}}}